pp 1–5 | Cite as

Prolactinomas in pregnancy: considerations before conception and during pregnancy

  • Andrea Glezer
  • Marcello D. BronsteinEmail author


Prolactinomas are the most common pituitary tumors and pathological hyperprolactinemia. Therefore, women harboring prolactinomas frequently present infertility due to the gonadal axis impairment. The gold-standard treatment is dopamine agonist (DA) which can reverse hyperprolactinemia and hypogonadism, and promote tumor shrinkage in the majority of cases. Therefore, reports of pregnancy in such cohort become more common. In this scenario, bromocriptine is still the DA of choice due to its shorter half-life and larger experience as compared to cabergoline. In DA resistant cases, transsphenoidal pituitary surgery is indicated. However, potential risks of DA-induced pregnancies include fetal exposition and symptomatic tumor growth. Dopamine agonist should be discontinued as soon as pregnancy is confirmed in microprolactinomas and intrasellar macroprolactinomas (MAC). Concerning expansive/invasive MAC, DA maintenance should be considered. Periodically clinical evaluation should be performed during pregnancy, being sellar imaging indicated if tumor symptomatic growth is suspected. In such cases, if DA treatment fails, neurosurgery is indicated.


Infertility Prolactinoma Pregnancy Bromocriptine Cabergoline 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Colao A, Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352(9138):1455–1461PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Colao A, Di Sarno A, Cappabianca P, Briganti F, Pivonello R, Di Somma C et al (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Sonigo C, Bouilly J, Carré N, Tolle V, Caraty A, Tello J, Simony-Conesa FJ, Millar R, Young J, Binart N (2012) Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest. 122(10):3791–3795PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Millar RP, Sonigo C, Anderson RA, George J, Maione L, Brailly-Tabard S, Chanson P, Binart N, Young J (2017) Hypothalamic-pituitary-ovarian axis reactivation by kisspeptin-10 in hyperprolactinemic women with chronic amenorrhea. J Endocr Soc 1(11):1362–1371PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Bronstein M (2010) Disorders of prolactin secretion and prolactinomas. In: Larry Jameson J, De Groot LJ (eds) Endocrinology: adult and pediatric. 1, 6th edn. Philadelphia, Saunders, pp 104–128Google Scholar
  6. 6.
    Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine Society (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Glezer A, Bronstein MD (2015) Prolactinomas. Endocrinol Metab Clin N Am 44(1):71–78CrossRefGoogle Scholar
  8. 8.
    Molitch ME (2015) Endocrinology in pregnancy: management of the pregnant patient with a PRLoma. Eur J Endocrinol 172(5):R205–R213PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Foyouzi N, Frisbaek Y, Norwitz ER (2004) Pituitary gland and pregnancy. Obstet Gynecol Clin N Am 31:873–892 (xi) CrossRefGoogle Scholar
  10. 10.
    Rigg LA, Lein A, Yen SSC (1977) Pattern of increase in circulating PRL levels during human gestation. Am J Obstet Gynecol 129:454–456PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Ferriani RA, Silva de Sa MF, Lima Filho EC (1986) A comparative study of longitudinal and cross-sectional changes in plasma levels of PRL and estriol during normal pregnancy. Braz J Med Biol Res 19:183–188PubMedPubMedCentralGoogle Scholar
  12. 12.
    Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso HÅ, Idahl A, Lehtinen M, Surcel HM, Fortner RT (2016) Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth 16(1):146PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Huang W, Molitch ME (2019) Pituitary tumors in pregnancy. Endocrinol Metab Clin N Am 48(3):569–581CrossRefGoogle Scholar
  14. 14.
    Colao A (2009) Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23(5):575–596PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Ikeda H, Watanabe K, Tominaga T et al (2013) Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg 115(9):1621–1625PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Yan Z, Wang Y, Shou X et al (2015) Effect of transsphenoidal surgery and standard care on fertility related indicators of patients with prolactinomas during childbearing period. Int J Clin Exp Med 8(11):21557–21564PubMedPubMedCentralGoogle Scholar
  17. 17.
    Yi N, Ji L, Zhang Q, Zhang S, Liu X, Shou X, Lu B (2018) Long-term follow-up of female prolactinoma patients at childbearing age after transsphenoidal surgery. Endocrine 62:76–82PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Grand’Maison S, Weber F, Bédard M-J, Mahone M, Godbout A (2015) Pituitary apoplexy in pregnancy: a case series and literature review. Obstet Med 8(4):177–183PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Oğuz SH, Soylemezoglu F, Dagdelen S, Erbas T (2019) A case of atypical macroprolactinoma presenting with pituitary apoplexy during pregnancy and review of the literature. Gynecol Endocrinol. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lamberts SWJ, Klijn JGM, de Lange SA et al (1979) The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with radiologically evident pituitary tumors. Fertil Steril 31:614–619PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    O’Donovan PA et al (1986) Apoplexy into a prolactin secreting macroadenoma during early pregnancy with successful outcome: case report. Br J Obstet Gynaecol 93:389–391PubMedPubMedCentralGoogle Scholar
  22. 22.
    Freeman R, Wezenter B, Silverstein M et al (1992) Pregnancy-associated subacute hemorrhage into a prolactinoma resulting in diabetes insipidus. Fertil Steril 58:427–429PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Gondim J et al (2003) Minimally invasive pituitary surgery in a hemorrhagic necrosis of adenoma during pregnancy. Minim Invasive Neurosurg 46:173–176PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Parihar V, Yadav YR, Sharma D (2009) Pituitary apoplexy in a pregnant woman. Ann Indian Acad Neurol 12:54–55PubMedPubMedCentralGoogle Scholar
  25. 25.
    Ginath S, Golan A (2010) Images in clinical medicine. Gestational pituitary tumor apoplexy. N Engl J Med. 363:e10PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Couture N, Aris-Jilwan N, Serri O (2012) Apoplexy of a microprolactinoma during pregnancy: case report and review of literature. Endocr Pract 18:e147–e150PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Witek P et al (2012) Transsphenoidal surgery for a life-threatening prolactinomas apoplexy during pregnancy. Neuro Endocrinol Lett 33:483–488PubMedPubMedCentralGoogle Scholar
  28. 28.
    Janssen NM, Dreyer K, van der Weiden RM (2012) Management of pituitary tumour apoplexy with bromocriptine in pregnancy. JRSM Short Rep 3:1CrossRefGoogle Scholar
  29. 29.
    Chegour H, El Ansari N (2014) Pituitary apoplexy during pregnancy. Pan Afr Med J 17:211PubMedPubMedCentralGoogle Scholar
  30. 30.
    Tandon A, Alzate J, LaSala P et al (2014) Endoscopic endonasal transsphenoidal resection for pituitary apoplexy during the third trimester of pregnancy. Surg Res Pract 2014:397131PubMedPubMedCentralGoogle Scholar
  31. 31.
    Hayes AR, O’Sullivan AJ, Davies MA (2014) A case of pituitary apoplexy in pregnancy. Endocrinol Diabetes Metab Case Rep 2014:140043PubMedPubMedCentralGoogle Scholar
  32. 32.
    De Ycaza AE, Chang AY, Jensen JR et al (2015) Approach to the management of rare clinical presentations of macroprolactinomas in reproductive-aged women. Case Rep Womens Health 8:9–12PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Grand’Maison S et al (2015) Pituitary apoplexy in pregnancy: a case series and literature review. Obstet Med 8:177–183PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Querol Ripoll R, Camara Gomez R, del Olma Garcıa M et al (2015) Pituitary apoplexy in a pregnant woman with cystic microprolactinoma. Endocrinol Nutr 62:200–202PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Glezer A, Jallad RS, Machado MC, Fragoso MC, Bronstein MD (2016) Pregnancy and pituitary adenomas. Minerva Endocrinol 41(3):341–350PubMedPubMedCentralGoogle Scholar
  36. 36.
    Holmgren U, Bergstrand G, Hagenfeldt K, Werner S (1986) Women with PRLoma—effect of pregnancy and lactation on serum PRL and on tumour growth. Acta Endocrinol (Copenh) 111(4):452–459CrossRefGoogle Scholar
  37. 37.
    Persiani S, Sassolas G, Piscitelli G et al (1994) Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci 83(10):1421–1424PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
  39. 39.
  40. 40.
    Krupp P, Monka C, Richter K (1988) The safety aspects of infertility treatments. In: Program of the second world congress of gynecology and obstetrics, Rio de Janeiro, p 9Google Scholar
  41. 41.
    Raymond JP, Goldstein E, Konopka P, Leleu MF, Merce-ron RE, Loria Y (1985) Follow-up of children born of bromocriptine-treated mothers. Horm Res 22:239–246PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Canales ES, Garcia IC, Ruiz JE, Zárate A (1981) Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril 36:524–526PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Konopka P, Raymond JP, Merceron RE, Seneze J (1983) Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 146:935–938PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Ruiz-Velasco V, Tolis G (1984) Pregnancy in hyperprolactinemic women. Fertil Steril 41:793–805PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Glezer A, Bronstein MD (2014) Prolactinomas, cabergoline, and pregnancy. Endocrine 47:64–69PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Rastogi A, Bhadada SK, Bhansali A (2017) Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol Endocrinol 33(4):270–273PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Lambert K, Rees K, Seed PT, Dhanjal MK, Knight M, McCance DR, Williamson C (2017) Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes. Obstet Gynecol 129(1):185–194PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Bronstein MD (2005) Prolactinomas and pregnancy. Pituitary 8:31–38PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R et al (2010) High-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95:2672–2679PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 73:236–242Google Scholar
  51. 51.
    Stalldecker G, Gil MSM, Guitelman MA et al (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13:345–350PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das ClinicasUniversity of Sao Paulo Medical SchoolSão PauloBrazil

Personalised recommendations